

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR CLINICAL TRIALS IN BOTH CHINA AND U.S. FOR
ITERATIVE MRNA HERPES ZOSTER VACCINE
ITS HUMORAL AND CELLULAR IMMUNITY WAS SIGNIFICANTLY
HIGHER THAN THOSE OF INTERNATIONAL BENCHMARK
PRODUCTS

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors of the latest business developments of the Group.

Following its approval for clinical trials by the U.S. Food and Drug Administration (“**FDA**”) in March 2025, the mRNA herpes zoster vaccine developed by the Group has recently received the Drug Clinical Trial Approval Notice (《藥物臨床試驗批准通知書》) from the National Medical Products Administration. The dual approval for the vaccine in both China and the U.S. fully demonstrates the strength of the Group’s mRNA technology platform.

In preclinical testing, results from a third-party testing unit showed that the Group’s mRNA herpes zoster vaccine specific T-cell immunity, specific IgG antibody titers, and fluorescent antibody to membrane antigen (FAMA) titers were significantly higher than those of international commercially available recombinant subunit control vaccines.

Herpes zoster is an infectious dermatosis caused by reactivation of the varicella-zoster virus (VZV), which has been latent in the body for a long time. The general population is universally susceptible to VZV, and serological evidence indicates that the infection rate of VZV among adults exceeds 90%. The incidence rate of herpes zoster is 3‰ to 5‰ person/year, and 3‰ to 10‰ person/year in the Asia-Pacific region, with an annual increase of 2.5% to 5.0%. For people aged 50 or above, VZV-specific cellular immune function gradually

decreases with age. As a result, the incidence, hospitalization rate and case fatality rate of herpes zoster gradually increase. The recurrence rate of herpes zoster is 1% to 10%, and its risk factors include advanced age, immunodeficiency and chronic diseases. Vaccination against herpes zoster is an effective measure to inhibit the onset of herpes zoster. The herpes zoster vaccine is vaccinated to prevent herpes zoster, postherpetic neuralgia (PHN) and other complications by inhibiting VZV reactivation.

Currently, no mRNA herpes zoster vaccine has been approved for marketing in the world. The vaccination rate of herpes zoster vaccines among the target population in China is less than 1%, leaving much room for improvement. In 2024, the global sales of GSK herpes zoster vaccines reached approximately US\$4.310 billion. According to the forecast of China Insights Industry Consultancy Limited, an industry consultant, it is expected that the market size of herpes zoster vaccines in China will reach approximately RMB20.0 billion and the global market size will reach approximately US\$23.9 billion by 2030. Upon approval of the product for marketing, it will bring considerable growth to the Group's performance. The mRNA herpes zoster vaccine of AIM is expected to reshape the market landscape due to its advantages in terms of safety and immunogenicity.

The Group is one of the enterprises that takes the lead in developing mRNA vaccine products in China, and also one of the first batch of domestic vaccine enterprises that has obtained an independent patent for mRNA technology. The Group has a mature mRNA vaccine research and development system. The Group has now smoothened the entire industrialization process such as the research, development and production of mRNA vaccines, allowing for rapid achievement of the industrialization of mRNA vaccine products after obtaining clinical approval and accelerating the commercialization process of vaccine products. In the future, the Group will continue to focus on the key technologies of the mRNA platform, and on this basis, rapidly advance the research, development and registration of new products. The Group will focus on addressing the unmet clinical needs in core disease areas and continue boosting the Company's innovation capabilities, core competitiveness, and overall strength.

By order of the Board
AIM Vaccine Co., Ltd.

Chairman of the Board and CEO Mr. Yan ZHOU

Hong Kong, May 19, 2025

As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN and Mr. Jie ZHOU as executive Directors; Mr. Jichen ZHAO as non-executive Director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive Directors.